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A B S T R A C T
For radiotherapy of prostate cancer, MRI is used increasingly for delineation of the prostate gland. For
focal treatment of low-risk prostate cancer or focal dose escalation for intermediate and high-risk cancer,
delineation of the tumor is also required. While multi-parametric MRI is well established for detection
of tumors and for staging of the disease, delineation of the tumor inside the prostate is not common
practice.
Guidelines, such as the PI-RADS classiﬁcation, exist for tumor detection and staging, but no such guide-
lines are available for tumor delineation. Indeed, interobserver studies show substantial variation in tumor
contours. Computer-aided tumor detection and delineation may help improve the robustness of the in-
terpretation of multi-parametric MRI data. Comparing the performance of an earlier developed model
for tumor segmentation with expert delineations, we found a signiﬁcant correlation between tumor prob-
ability in a voxel and the number of experts identifying this voxel as tumor. This suggests that the model
agrees with ‘the wisdom of the crowd’, and thus could serve as a reference for individual physicians in
their decision making.
With multi-parametric MRI it becomes feasible to revisit the GTV-CTV concept in radiotherapy of pros-
tate cancer. While detection of index lesions is quite reliable, contouring variability and the low sensitivity
to small lesions suggest that the remainder of the prostate should be treated as CTV. Clinical trials that
investigate the options for dose differentiation, for example with dose escalation to the visible tumor or
dose reduction to the CTV, are therefore warranted.
© 2016 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Radiotherapy for prostate cancer has been proven an effective
form of treatment and is to date one of the standard treatment
options available. The current practice is to treat the entire pros-
tate with a more or less homogeneous dose. This is remarkable, as
it is well known that tumors are distributed inhomogeneously inside
the prostate. Already in 2000, Chen et al. [1] showed in 180 pros-
tatectomy specimen that 74% of the cancer foci were located in the
peripheral zone. In 83% of patients, more than one tumor focus was
found. Hollmann et al. [2] showed in 61 prostatectomy specimens
that the index lesions, deﬁned as the largest tumor inside a pros-
tate, accounted for 88% of the total tumor volume. The contribution
of tumor foci < 0.1 cm3 to the total tumor volume was 2%. Ou et al
[3] constructed statistical atlases of the presence of prostate cancer* Corresponding author. Department of Radiation Oncology, the Netherlands Cancer
Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel.:
+31205122350.
E-mail address: u.vd.heide@nki.nl (U.A. van der Heide).
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1120-1797/© 2016 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. Th
creativecommons.org/licenses/by-nc-nd/4.0/).based on 83 prostatectomy specimens, showing the probability of
ﬁnding a tumor at a particular location.
Multi-parametric MRI (mp-MRI) is now well established for de-
tection of tumors inside the prostate gland and staging of the disease
[4–6]. For tumor detection, a protocol consisting of T2-weightedMRI,
diffusion-weighted MRI (DWI) and Dynamic Contrast-Enhanced
(DCE-) MRI is recommended [7,8]. The recently published Pros-
tate Imaging – Reporting And Data System (PI-RADS) version 2 [9,10]
is designed to improve detection, localization, characterization, and
risk stratiﬁcation in patients with suspected cancer in treatment
naive prostate glands.
In radiotherapy, the contouring of the prostate gland is usually
based on CT images as planning CT scans form the basis for dose
calculations. However, as MRI-based contouring resulted in a smaller
target volumes [11], this is now used increasingly for delineation
of the prostate gland. Image registration between MRI and plan-
ning CT scan is required, unless hounsﬁeld unit images can be derived
from the MR images directly [12,13]. Traditionally, the entire pros-
tate is treated with a more or less homogeneous dose. To improve
the therapeutic window between tumor control and toxicity, for low-
risk patients, focal treatment options are now considered. Foris is an open access article under the CC BY-NC-ND license (http://
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proach can deliver an extremely high dose to the tumor while
satisfying dose constraints to normal tissue.
Delineation of the tumor and differentiation of the radiation dose
between MRI-visible tumor (Gross target volume, GTV) and the re-
mainder of the gland (Clinical target volume, CTV) is not standard
practice [14]. Nevertheless, several planning studies showed the po-
tential for dose escalation to the MRI-visible tumor with external-
beam radiotherapy [15,16]. Rylander et al. [17] showed that a
combination of dose escalation to the tumor, combined with a de-
escalation of the dose to the remainder of the gland is feasible with
125-Iodine seed implant brachytherapy. Two phase III random-
ized trials investigate the clinical beneﬁt of focal escalation of the
dose to the tumor as deﬁned on mp-MRI (FLAME (NCT01168479))
[18], HEIGHT (NCT01411332), but clinical results are as yet not
available.
We here review the use of MRI in a diagnostic setting, for staging
and tumor detection. We then evaluate how MRI is used for target
delineation for radiotherapy. As target delineation is one of the crit-
ical steps in the radiotherapy chain, automatic segmentation of
images has received increasing interest. For tumors inside the pros-
tate, computer-aided tumor detection is an exciting development
that may improve the quality and consistency of interpretation of
mp-MRI.
In this study, we therefore also apply our earlier developedmodel
for tumor segmentation [19] to the group of patients that was used
in our recent study of interobserver variability [20]. This allows us
to establish the quality of the model results relative to the manual
segmentations and evaluate its potential for improving tumor de-
lineation consistency.
MRI for prostate cancer staging and tumor detection
The use of functional MRI techniques in combination with T2-
weighted MRI has been reviewed extensively [4–6]. DWI reﬂects
tissue cellularity and membrane integrity and is quantiﬁed by the
Apparent Diffusion Coeﬃcient (ADC), representing the diffusion co-
eﬃcient of water molecules in the tissue. DCE-MRI reﬂects micro-
vessel density and permeability. The data can be quantiﬁed using
tracer kineticsmodeling. Themost commonly usedmodel is the Tofts
model [21] that yields the transfer constant Ktrans, representing blood
ﬂow and permeability. MR Spectroscopic Imaging (MRSI) shows the
relative concentrations of metabolites in cancerous and normal pros-
tate tissue.
Combining T2-weighted MRI, DWI and DCE-MRI, Tanimoto et al.
[22] found an area under the receiver operating curve (AUC) for the
detection of prostate cancer of 0.966. Reinsberg et al. [23] com-
bined choline/citrate ratios obtained from MRSI with ADC values
from DWI and found an AUC of 0.98 when considering voxels pos-
itive when containingmore than 70% tumor. Isebaert et al. [24] found
that DWI had the highest accuracy for tumor localization com-
pared to T2w and DCE-MRI, with more aggressive or more advanced
tumors being more easily detected. Signiﬁcantly higher sensitivi-
ty values were obtained for the combination of T2w, DCE, and DWI
as compared to each modality alone or any combination of two
modalities.
A confounding factor in tumor detection with mp-MRI, partic-
ularly when using T2w and DCE imaging, is the presence of post-
biopsy hematoma. To minimize this effect in a diagnostic setting,
MRI scans are usually made at least 6 weeks after biopsies were
taken. However, patients scheduled for treatment with radiother-
apy often have ﬁducial markers implanted for position veriﬁcation
during external-beam radiotherapy [25]. As the implantation of these
ﬁducial markers also may cause hematoma, it is relevant to include
a T1-weighted sequence in the MRI exam which visualizes hema-
toma as hyperintense areas inside the prostate gland.
Recently, an expert panel of the European Society of Urogenital
Radiology (ESUR), acknowledging that true evidence-based guide-
lines could not be formulated, presented minimum and optimum
requirements [7] as did Dickinson et al. [8], specifying each se-
quence in detail. For tumor detection, a protocol consisting of T2-
weightedMRI, DWI and DCE-MRI is recommended.MR spectroscopic
imaging is considered optional.
An important element in the ESUR consensus paper is the PI-
RADS. This provides a structured reporting scheme, where for each
of the imaging modalities score criteria are deﬁned that reﬂect
aspects that relate to the presence of cancer. The combined scores
are summarized in a single PI-RADS score, identifying from 1 to 5
the likelihood of cancer presence [7]. In the recently updated (PI-
RADS version 2) [9,10], different parameter scores are no longer
added, but instead priorities are given to the different parameters.
For the peripheral zone, the deciding factor in the overall score is
determined by DWI. For the transition zone, this is T2-weighted
imaging. As DCE-MRI in the transition zone can also reﬂect benign
prostate hyperplasia, its role has diminished.
There are some data on the detection limit of MRI techniques.
Schmuecking et al. [26] showed that for DCE-MRI, lesions smaller
than 3 mm and/or containing less than 30% cancer cells were not
detected. For MRSI, the cut-off level was 4mm and/or less than 40%
tumor cell content. Langer et al. [27] found in a study of T2-
weighted MRI and DWI that tumors with more than 50% of the area
occupied by normal peripheral zone tissue, exhibited T2 and ADC
values similar to normal tissue. Thus, the detectability of a lesion
depends on both its size and relative tumor content. Turkbey et al.
[28] showed a reduced sensitivity and speciﬁcity of tumor detec-
tion for lesions smaller than 5 mm and with a Gleason score 7 or
less. The impact on delineation accuracy is however unclear.
Several studies showed that a low ADC value is associated with
a higher Gleason score [29,30]. Somford et al. [31] found that DWI
predicts the presence of high-grade tumor in patients with Gleason
<6 on biopsies. This suggests that DWI is particularly suitable to
detect the more aggressive tumors [32]. Androgen deprivation
therapy (ADT) has also been shown to reduce tumor conspicuity
on MRI [33]. This is relevant for patients who after their initial di-
agnosis started with ADT before their referral to a radiotherapy
department.
Overall, we can conclude that mp-MRI is well established in the
diagnostic setting. Guidelines are now available for acquisition of
the data and the PI-RADS system provides a framework for sys-
tematic reporting, that reﬂects the certainty about tumor presence.
Chang et al. [34] showed in a retrospective study of 115 patients
that inclusion of MRI staging information improved incorporation
of extracapsular extension and seminal vesicle invasion in the target
in 20% of the patients. Thus, MRI scans can signiﬁcantly change de-
cisions about target coverage in radical radiotherapy for prostate
cancer.
Multi-parametric MRI for delineation of GTV and CTV
In contrast to the diagnostic practice, delineation of the CTV (pros-
tate with or without seminal vesicles) in radiotherapy ismostly based
on CT for external-beam radiotherapy and ultrasound for
brachytherapy. On CT, large inter-observer variations were found par-
ticularly at the base and apex of the prostate and around the seminal
vesicles [35]. MRI is superior to CT for localization of the prostatic
apex [36]. Rasch et al. [11,37] found that on CT, a 1.4 times larger
volume was delineated as prostate than on MRI, but no signiﬁcant
differences in interobserver variability were found. To help radia-
tion oncologists to use T2-weighted MRI in combination with CT
for target delineation, Villeirs et al. [38] described some key radio-
logic landmarks that can improve treatment planning, by offering
a clear depiction of the prosatic capsule separating the CTV from
the rectum and levator ani muscle, the ﬁbromuscular stroma an-
teriorly and the transition from normal periopheral zone to
ﬁbromuscular tissue caudally. Recently, Sander et al. [39] studied
toxicity in 72 patients with CT-based delineations and 73 patients
with MRI based delineations prior to radiotherapy. The smaller CTV
volume resulting from MRI delineation leads to signiﬁcantly lower
urinary frequency and urinary retention toxicity scores. However,
no signiﬁcant differences in overall urinary or rectal toxicity were
found between the two groups.
While MRI helps reduce the volume of delineated target struc-
tures, and improves coverage of extracapsular extension and seminal
vesicle invasion, the key advantage of MRI lies in the visualization
of tumors inside the prostate gland. Here, the same sequences are
used as for diagnostic MRI. Whereas a high level of expertise is re-
quired for staging and tumor localization, this is even more so for
delineation of the GTV where the boundaries of the tumor need to
be deﬁned. Unfortunately, to date no guidelines are available about
using mp-MRI for tumor delineations. Indeed, large variations in
tumor delineations are reported, with kappa values for region-
based tumor detection ranging from 0.40 to 0.63 [40,41].
In a study of 5 patients, the voxel-by-voxel kappa value, indi-
cating the intra-observer agreement between 5 observers, ranged
from 0.22 to 0.73 [42]. Anwar et al. [43] compared delineations by
two observers on T2w imaging and MR spectroscopy with delin-
eations on histology and found these to differ by a median distance
of 1.4 mm.
Recently, we studied the agreement between tumor delinea-
tions by 6 teams of radiation oncologists and radiologists from 3
centers, and validated this with whole mount histopathology speci-
mens [20]. For 20 patients, 18 index lesions were consistently
identiﬁed by all observers. The kappa indices for the agreement
between the delineations of the teams were 0.61 ± 0.19 (mean ± SD)
and the inter-observer contour standard deviation, deﬁned as the
standard deviation of the perpendicular distance of each obser-
ver’s contour relative to a reference, was 2.3 mm. In addition, 66
out of 69 satellites were missed by all observers. In the analysis of
clinical studies of focal dose escalation, these uncertainties need to
be considered.
Computer-aided tumor detection and delineation
To increase the robustness of the interpretation of mp-MRI data,
Rouviere et al. [44] showed that simple combinations of shape and
signal abnormalities in mp-MRI could be used to stratify the risk
of malignancy of focal abnormalities in the prostate. Several alter-
native methods have been proposed to extract relevant features for
each voxel for classiﬁcation into normal and tumor tissue using basic
classiﬁers such as support vector machines [45] and logistic re-
gression [19,46,47].
Viswanath et al. [48] use texture features such as Gabor wavelet
and Haar wavelet transformation extracted from the T2w-MRI scan
to represent each voxel. Groenendaal et al. [19] represent each voxel
by several local statistics, e.g. minimum, maximum and median of
intensities obtained on ADC and Ktrans maps. After logistic regres-
sion, the model provides the probability of tumor presence in
individual voxels in mp-MRI. Validation with whole-mount section
histology in 12 patients showed an area under the curve of 0.89 for
voxels in the peripheral zone of the prostate.
Another approach is to detect regions of interest in the pros-
tate using clustering [49]. Vos et al. [50] used a two-step approach
based on a combination of features from T2w, T1, pharmacoki-
netic and ADC maps. Texture features, such as blobness, were also
used to improve its performance. Nevertheless, it is hard to distin-
guish prostate cancer from confounders such as benign
prostatic hyperplasia (BPH), post-biopsy hemorrhage, and atrophy
[51,52].
Inter-observer variability and automated tumor delineation
In clinical practice, usually only one radiation oncologists de-
lineates a tumor. A delineation, essentially, is a binary decision about
voxels being part of the tumor or not. A radiologist can use the PI-
RADS score to reﬂect certainty about the detection of a tumor. A
similar system for radiotherapy is however not available. Never-
theless, the study of Steenbergen et al. [18] shows substantial inter-
observer variation in delineation. Particularly near the boundary of
the tumor, the variation in the delineations of the group of observ-
ers reﬂects the uncertainty about deﬁning this boundary.
The question is now how automated methods for tissue classi-
ﬁcation in terms of tumor probability relate to the variability of
tumor delineations of a group of expert observers. To this end, we
applied the model developed earlier by Groenendaal et al. [19] to
the group of patients used in the tumor delineation study of
Steenbergen et al. [20]. The mp-MRI scan consisted of T2-weighted,
DWI and DCE-MRI. Details of the scan protocol and quantitative anal-
ysis can be found in [20]. In short, ADC maps were calculated using
b-values, representing degrees of diffusion weighting, of 0, 50, 100,
500, 750 and 1000 s/mm2. For tracer kinetics modeling of the DCE-
MRI data, the signal intensities were ﬁrst converted to gadolinium
concentration values [53] using reference T1 values [54]. The ex-
tended Tofts model [21] was ﬁtted to the concentration time curves
for estimation of the volume transfer constant (Ktrans) using the
method by Murase et al. [55] with a population-based arterial input
function. Following [19], the Ktrans mapwas normalized to themedian
value of Ktrans in the peripheral zone, to account for measurement
variability. Also, all of the parametric maps (T2w, ADC, and Ktrans)
were resampled to a grid of 2.5 × 2.5 × 2.5 mm3.
A drawback of the model of Groenendaal [19] is that it was
trained by considering delineations of tumors on mp-MRI of 87 pa-
tients by radiation oncologists as ground truth, rather than
histopathology. We therefore took the same model structure, but
retrained it on the cohort used in the delineation study, using de-
lineations of the pathologist on hematoxylin-eosin (H&E) stained
slides as ground truth. Each H&E stained slide was registered to the
corresponding T2w MRI slice by means of a deformable point-
based method (Coherent Point Drift) using landmark points which
were visible on both images. This resulted in an average error of
2.1 mm (maximum 5mm) [20]. Then we tested the model perfor-
mance in a leave-one-out design. To account for registration errors
between MRI and the hematoxylin-eosin stained slides, we ex-
cluded voxels that were within a band of 2.5 mm around the tumor
boundary (1.25 mm inside and 1.25 mm outside the boundary), as
indicated by the pathologist. The area under the ROC curve for a
voxel-by-voxel analysis of the peripheral zone had a median of 0.87
(range 0.52–0.99) over the whole patient population. AUCs of two
patients were not calculated since there was no tumor in the pe-
ripheral zone of these patients. An example of the tumor probability
derived from mp-MRI is shown in Fig. 1.
The concept of tumor probability should not be confused with
cell density. The latter is a histological property indicating the tissue
architecture. A higher cell density (cellularity) can be detected with
diffusion-weighted MRI and is associated with cancer. The tumor
probability is related to target deﬁnition and reﬂects uncertainty
about the presence of tumor in a voxel. Where the tumor delinea-
tion of a radiation oncology essentially gives a binary classiﬁcation
of each voxel, the tumor probability provides a non-binary assess-
ment. This implies that for a perfectly calibratedmodel, in 100 voxels
that each have a probability of tumor presence of 50%, the histol-
ogy indeed should show that 50% of those voxels contain tumor and
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50% do not. Figure 2 plots the % of voxels with proven tumor in our
cohort as a function of their predicted probability of tumor pres-
ence. Ideally, a model should show the dashed line. The solid line
in the ﬁgure shows that the model is well calibrated with a tumor
prevalence value of 26%, which is close to the value found for the
peripheral zone in the histological data of this cohort.
Although an individual delineation is a binary classiﬁcation, this
doesn’t mean that the radiation oncologist and radiologist have com-
plete certainty. The variability between multiple observers is in part
a reﬂection of this uncertainty. To evaluate the relation between ob-
server variability and the model prediction, we therefore plotted
the tumor probability as a function of the number of teams of ob-
servers that had labeled the voxel as tumor for all voxels in the
peripheral zone. Figure 3 shows that for those voxels that were
labeled by all 6 teams as tumor, the model value for tumor prob-
ability indeed is high, with a median of 0.78. On the other hand,
for voxels that were labeled by all 6 teams as non-tumor, themedian
tumor probability is 0.08. Interestingly, for voxels that were iden-
tiﬁed by an intermediate number of teams, intermediate tumor
probabilities are found. The correlation between tumor probabili-
ty and the number of teams identifying a voxel as a tumor is highly
signiﬁcant with a p-value < 0.001 and a moderately high Spear-
man correlation coeﬃcient of 0.56. The concept of tumor probability
is attractive for radiotherapy as it represents the certainty about
tumor presence, but also correlates with the level of consensus in
a group of observers. For dose differentiation between tumor and
the remainder of the prostate, rather than stratiﬁcation in distinct
dose levels, the probabilistic interpretation of dose painting could
be adopted, gradually modulating the dose based on tumor
probability.
Figure 1. Examples from 5 patients. From left to right: T2w; ADC; Ktrans, H&E staining, tumor probability. The green and red contours in the tumor probability maps rep-
resent the peripheral zone region and the estimated tumor area by the model, respectively.
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Discussion and conclusion
Multi-parametric MRI is well established as a tool for staging of
prostate cancer and detection of tumors inside the gland and seminal
vesicles. The use of T2-weighted MRI for delineation of the pros-
tate gland for radiotherapy results in target volumes that are about
30% smaller as compared to CT. This results in an implicit reduc-
tion of the CTVmargin around the prostate, and leads to a reduction
in treatment-related toxicity. However, for patients with extracap-
sular extension of the disease, an adequate CTV margin is required
to account for subclinical disease outside the gland.
The key advantage of mp-MRI lies in the visualization of tumors
inside the prostate. While the accuracy of tumor detection is high,
interobserver variability in tumor delineation is sizeable. The PI-
RADS system is an important step in reﬂecting the certainty about
tumor presence in radiology reporting. An analogous system for
radiotherapy tumor delineation could be helpful to indicate the cer-
tainty about parts of the delineation.
Automated methods for tumor detection may be helpful to
improve the quality of tumor delineation. However, the correspon-
dence of our tumor probability model with histology suggests that
a probabilistic approach provides a more appropriate description
of the pathology than a speciﬁc binary classiﬁcation. The correla-
tion between the tumor probability and number of observers
identifying a voxel as tumor suggests that the model agrees with
‘the wisdom of the crowd’, and thus could serve as a reference for
individual physicians in their decision making.
With mp-MRI it becomes feasible to revisit the GTV-CTV concept
in radiotherapy of prostate cancer. While detection of index lesions
is quite reliable, contouring variability and the low sensitivity to small
lesions suggest that the remainder of the prostate should be treated
as CTV. Clinical trials that investigate the options for dose differ-
entiation, for example, with escalation to the visible tumor or dose
reduction to the CTV, are therefore warranted.
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